Bis-5 is under clinical development by L&L Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bis-5’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bis5 (LB-1410) is under development for the treatment of solid tumors and lymphomas, non-small cell lung cancer, small cell lung cancer, endometrial cancer, anal cancer, ovarian cancer, head and neck squamous cell carcinoma, gastric adenocarcinoma or gastroesophageal junction cancer. It is administered through intravenous route. The therapeutic candidate is a bi-specific antibody which acts by targeting PD-1 and TIM-3.
L&L Biopharma overview
L&L Biopharma is engaged in the research and development of new drugs for tumor immunotherapy. L&L Biopharma is headquartered Shanghai, China.
For a complete picture of Bis-5’s drug-specific PTSR and LoA scores, buy the report here.